We integrate our Sector’s broad portfolio of technologies to create unique solutions for the prediction, prevention and treatment of complex diseases, including cancer, cardiovascular disease and neurological disorders. Our mission is to optimize current clinical best practices and establish new standards of care in order to maximize quality while minimizing costs.
Thomas Miller, CEO
We’re unique in our industry, developing and aligning technologies from a disease-centric and, ultimately, patient-centric perspective – an untapped market of tremendous potential. Our objective is twofold: to create demand by offering cohesive solutions that integrate our portfolio of products and services; and to generate value which exceeds that of standalone products.
Such an approach cannot be created in isolation. That’s why we’re working with healthcare institutions and clinical experts in academia, research and tertiary care to identify, replicate, automate and continuously innovate global best practices in treating the most common, complex and serious diseases.
Today’s global healthcare environment increasingly operates under the intense pressure of pay-for-performance models and quality outcomes measurement. Hospitals certified as centers of excellence for stroke, cardiovascular disease and other illnesses submit to annual audits and provide continuous quality data reporting. This increased scrutiny is not limited to the industry and peer review. Consider the US Government’s 2008 landmark decision to provide consumers with hospital outcomes rankings for diseases including pneumonia and myocardial infarction.
In cases of acute coronary syndrome, for example, workflow and clinical accuracy can mean the difference between life and death. Standards established by the Joint Commission on Accreditation of Hospitals in the U.S. stipulate a 90-minute door-to-balloon time for patients exhibiting acute coronary syndrome. Yet emergency room waiting times alone average 50 minutes for patients with chest pains. Our best practice consulting helps customers not just meet the Joint Commission goals but cut treatment times in half. In addition, clinical trials are underway on a totally new workflow leveraging Siemens’ innovative blood tests and imaging technologies to accelerate differential diagnosis and minimize treatment risk – saving time, money and lives.
Our organization – including oncology, cardiology, neurology, women’s health, urology, surgery and audiology – reflects this disease-centered approach. We also direct the Healthcare Sector’s worldwide Customer Relationship Management and Customer Service. With our in-depth knowledge of clinical science and our customers’ clinical and business objectives, we’re leveraging our unparalleled portfolio of technologies to increase both market share and profitability.
Thank you for viewing Siemens' Annual Report 2008.
If you require further information, please contact us:
+49 (0)89 636-33032 (Press Office)
+49 (0)89 636-32474 (Investor Relations)
+49 (0)89 636-30085 (Press Office)
+49 (0)89 636-32830 (Investor Relations)
Please send the Annual Report 2008 to the following address: